Research summary
Research HubSS-31 (Elamipretide)
Clinical — 10 studies
SS-31 is a mitochondria-targeting tetrapeptide investigated for its role in improving mitochondrial function and reducing oxidative stress in cellular and animal models.
Being studied for
- Mitochondrial dysfunction
- Oxidative stress reduction
- Cellular energy metabolism
- Age-related tissue degeneration research
Published Research
Evidence profile
Human Phase 3 evidence
10 cited publications · 2 primary trials · 1 derived analysis
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
Thompson WR et al. · Genetics in medicine : official journal of the American College of Medical Genetics · 2024
The study reportedElamipretide was associated with sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac function in BTHS.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Karaa A et al. · Neurology · 2023
The study reportedSubcutaneous elamipretide treatment did not improve outcomes in the 6MWT and PMMSA TFS in patients with PMM. However, this phase-3 study demonstrated that subcutaneous elamipretide is well-tolerated.
Additional indexed literature (8)
- Clinical · Post-hoc analysisGenotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
Karaa A et al. · Orphanet journal of rare diseases · 2024 · PMID 39574155
- Preclinical · Mechanistic studyMechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion
Xie M et al. · Lung · 2026 · PMID 41801306
- Preclinical · Mechanistic studySS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting
Zheng H et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · PMID 39848110
- Preclinical · Mechanistic studyAging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening
Patai R et al. · GeroScience · 2025 · PMID 40169521
- Preclinical · Mechanistic studyALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease
Hao Y et al. · Cell communication and signaling : CCS · 2024 · PMID 38200543
- Preclinical · Mechanistic studyGenome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31
Silvaroli JA et al. · Journal of the American Society of Nephrology : JASN · 2024 · PMID 38530359
- Preclinical · Mechanistic studyElamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
Zhang H et al. · Journal of neuroinflammation · 2023 · PMID 36609266
- Preclinical · Mechanistic studyElamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages
Nie Y et al. · Antioxidants (Basel, Switzerland) · 2023 · PMID 38136142
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
SS-31 has been investigated in clinical research settings but is not broadly approved as a therapeutic product.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.